top of page

Free Biopharma Daily Stock Updates - 04/22/22

$XBI $79.84 | -1.63%

BiopharmIQ offers pro members full access to FDA Catalyst Calendar, PDUFA's, Biotech Stock Ideas.
 

Covid Updates

$NVAX -4.4% Novavax Announces Initiation of COVID-19 Vaccine Booster Study in Adolescents in Phase 3 PREVENT-19 Trial.


Pipeline Updates

$INCY -0.4% Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer.


$SCYX -25.8% SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections.


$AMPE +13.9% Receipt of written responses from the United States Food and Drug Administration (FDA) pursuant to a Type C meeting request submitted by the Company earlier in the year regarding the AP-013 trial results.


$CVM -9.5% CEL-SCI Announces Acceptance of Abstracts to ASCO 2022.


 

Want to get weekly catalyst updates?

*We never spam you - unsubscribe anytime*

 

Business Updates

$ITCI -5.9% Intra-Cellular Therapies initiated at neutral at Piper Sandler on current valuation.


$NKTR +1.3% Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors to Outline New Strategic Plan.


$OTLK -2.9% BioLexis Reorganization Results in GMS Holdings as Largest Shareholder in Outlook Therapeutics.


$VLON +100.9% Vallon Pharmaceuticals Announces Review of Strategic Alternatives


$SCYX -25.9% SCYNEXIS Announces Pricing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants.


$UTHR -1.4% Centers for Medicare and Medicaid Services (CMS) updated its Local Coverage Determination (LCD) for Tyvaso® (treprostinil) Inhalation Solution to include an indication for pulmonary hypertension associated with interstitial lung disease. CMS indicated that this LCD will take effect after a 45-day notice period, becoming effective on June 5, 2022.

 

Posted by DV/FS

0 comments

Comments


bottom of page